Our President & CEO, Mr. Hideaki Sato, will speak at RNA Leaders APAC 2026 in Singapore.

On September 1 at 2:30 PM local time, he will deliver a presentation titled:

“Driving innovation in antisense therapeutics for Intractable diseases using artificial nucleic acid technologies and ophthalmological applications”

In this presentation, we will introduce our proprietary nucleic acid therapeutics platform, LuxiAP™, and present our research and development efforts in next-generation antisense oligonucleotide therapeutics for intractable diseases.

The presentation will also highlight the application of our technologies to neurological and ophthalmological diseases, as well as recent progress in our in-house development program for glaucoma treatment.

We look forward to meeting researchers, industry partners, and innovators from across the RNA therapeutics community.

Click here for more details.